Skip to main content

ASCIA News

  • ASCIA Annual Conference and AIFA Research Grant Sponsorship
    Planning is now well underway for the ASCIA 2024 Conference which will provide an international standard of CPD for ASCIA members and other health professionals working in allergy and clinical immunology. It will also provide an opportunity for important in-person...
  • QR codes on ASCIA patient/carer information webpages
    To improve access and reduce the need for printing, QR codes have been added to each of the 15 ASCIA patient/carer information landing webpages that are accessed via https://www.allergy.org.au/patients/information Each of the following webpages include a QR code directly...
  • Recent National Allergy Council Updates
    Recent National Allergy Council Updates include: A link to patient and carer organisations added as the first tile on the ASCIA website homepage   A Survey to Improve Allergy Training in Tertiary Healthcare Degrees open until 17 March 2024, as part of the Shared Care...
  • Latest Versions of ASCIA Action Plans for Anaphylaxis - February 2024 Update
    Current ASCIA Action Plans are the 2023 versions. However, prior versions (2022 and 2021) are still valid for use in 2024. It is expected that it will take around 6-12 months to phase in the use of the new 2023 plans. The plans are available open access on the ASCIA...
  • PBAC Meeting March 2024 - ASCIA Submissions
    ASCIA has lodged five submissions on 24 January 2024 in support of applications for new or updated Pharmaceutical Benefits Scheme (PBS) listings of products (listed below) that are relevant to allergy and immunology. These applications are on the agenda of the  March 2024...
  • New ASCIA Newborn Screening Resources
    ASCIA has developed new resources to support newborn screening for Severe Combined Immune Deficiency (SCID), which is now available throughout Australia and New Zealand: Newborn Screening for Severe Combined Immune Deficiency (SCID) and BCG Vaccination - Position Statement for...
  • Updated ASCIA Adrenaline Injectors FAQ
    ASCIA Adrenaline Injectors Frequently Asked Questions (FAQ) has been updated to provide more information about PBS and Pharmac listings of adrenaline injectors in Australia and New Zealand. The updated FAQ is available on the ASCIA website https://www.allergy.org.au/hp/anaphylaxis/adrenaline-injectors-faqs The...
  • RSV Vaccine Approved by TGA
    AREXVY (GSK) is a vaccine for respiratory syncytial virus (RSV) which has been approved in Australia by the TGA for individuals 60 years and older for the prevention of lower respiratory tract disease caused by RSV. GSK is working to ensure national distribution of the...
ASCIA Member Login

Site last updated: 29 FEB 2024
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...